The CDSCO's expert panel has recommended the import and sale of Camizestrant for treating specific advanced breast cancer cases in India. By waiving local Phase III trials, regulators aim to speed up access for patients with ESR1 mutations. However, commercial success will depend on the availability of genetic testing and mandatory post-approval monitoring, while global trial setbacks for the drug’s use in other settings warrant investor attention.
AstraZeneca Pharma India has received a positive recommendation from the Central Drugs Standard Control Organization’s (CDSCO) Subject Expert Committee to import and market its breast cancer therapy, Camizestrant. The drug is intended for use in adult patients suffering from HR-positive, HER2-negative advanced breast cancer who have developed resistance to previous hormone therapies due to ESR1 mutations.
To expedite the availability of this targeted treatment, regulators granted a waiver for local Phase III clinical trials, citing a significant unmet medical need for patients with few remaining options. As part of the approval process, the company must submit a protocol for a Phase IV clinical trial—which monitors the drug’s safety and performance in the real world—within three months of final approval. Furthermore, the committee has mandated that the drug be prescribed only by qualified medical oncologists, given the need to manage potential side effects such as irregular heart rhythms and bradycardia.
While this recommendation marks a milestone for the company’s oncology portfolio in India, investors should note the specific operational and clinical challenges surrounding the drug. A primary logistical hurdle is the requirement for widespread, affordable ESR1 mutation testing. Without efficient screening protocols, many patients may not be identified as eligible candidates for this therapy, potentially limiting the market reach of the drug to major metropolitan cancer centers.
Additionally, the broader clinical outlook for Camizestrant has seen some mixed results globally. While the U.S. Food and Drug Administration granted accelerated approval for a combination therapy involving Camizestrant in September 2026, the drug faced a setback during the same month. A separate late-stage study, known as the SERENA-4 trial, failed to meet its primary goal of progression-free survival in previously untreated patients. This outcome limits the current therapeutic scope of the drug, making the targeted use in the specific ESR1-mutated population a key focus area for the company.
Moving forward, the company will need to focus on establishing the necessary testing infrastructure and ensuring compliance with the mandatory Phase IV trial protocols. The speed of adoption will depend on how quickly medical providers can integrate the required genetic screening into their routine oncology practices. Investors may track future exchange filings and management commentary regarding the pricing, distribution strategy, and progress of the post-approval safety studies.